Group 1 - The core point of the article is that Zhifei Biological has recently obtained a patent for a method to detect quality differences in immune adjuvants, which may enhance its product offerings and competitive edge in the biopharmaceutical industry [1] - Zhifei Biological's revenue composition for the year 2024 is heavily reliant on biological products, accounting for 99.14% of total revenue, indicating a strong focus on this segment [2] - As of the latest report, Zhifei Biological has a market capitalization of 49.7 billion yuan, reflecting its significant position in the market [3]